Sumitomo Pharma

Perfil de la empresa

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Drug Manufacturers - Specialty & Generic

País

Japón

Sede

2-6-8 Doshomachi, 541-0045, Osaka

Cotización

4506 · TSE

Índices

Nikkei 225

Divisa

JPY

ISIN

JP3495000006

Sitio web

sumitomo-pharma.com